Tazorac Gel
NDC Package 16110-042-30
Package Information
Tazorac (tazarotene) gel is tazarotene is used to treat psoriasis or acne. This formulation utilizes a gel delivery system. Marketed by Almirall, Llc, this product is identified by NDC 16110-042 and is authorized under FDA application NDA020600.
Identification & Billing
- RxCUI: 212437 - TAZORAC 0.05 % Topical Gel
- RxCUI: 212437 - tazarotene 0.0005 MG/MG Topical Gel [Tazorac]
- RxCUI: 212437 - Tazorac 0.0005 MG/MG Topical Gel
- RxCUI: 212437 - Tazorac 0.05 % Topical Gel
- RxCUI: 212437 - Tazorac 0.5 MG in 1 GM Topical Gel
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 16110 - Almirall, Llc
- 16110-042 - Tazorac
- 16110-042-30 - 1 TUBE in 1 CARTON / 30 g in 1 TUBE
- 16110-042 - Tazorac
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (16110-042). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 16110-042-30 identifies a specific commercial package of 1 tube in 1 carton / 30 g in 1 tube of Tazorac, a human prescription drug labeled by Almirall, Llc. This gel is formulated for cutaneous use and contains tazarotene as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Almirall, Llc on February 21, 2020. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Tazarotene is used to treat psoriasis or acne. It is a retinoid product related to Vitamin A. It works by affecting the growth of skin cells. The foam and lotion forms of this medication are only approved for use on acne.
How is this Almirall, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 16110004230. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.